MIRM Latest Headlines

Mirum Pharmaceuticals Earnings Call Signals Broadening Growth

at www.tipranks.com (Sat, 14-Nov 10:16 PM)

Buy Maintained at $202 as Positive Phase 3 AZURE Results Support Planned BLA

at www.tipranks.com (Wed, 11-Nov 7:35 AM)

Mirum succeeds in second late-stage trial for hepatitis D therapy

at seekingalpha.com (Tue, 10-Nov 1:26 PM)

Mirum’s Strong Bre-lovitug Profile and Commercial Potential Support a Buy Rating

at www.tipranks.com (Tue, 10-Nov 8:05 AM)

Mirum Pharmaceuticals Reports Positive Phase 3 Brelovitug Results

at www.tipranks.com (Tue, 10-Nov 7:58 AM)

Mirum’s Buy Rating Reaffirmed as Breviloitug Shows Durable HDV Suppression; $184 Price Target Unchanged

at www.tipranks.com (Tue, 10-Nov 6:36 AM)

Mirum sets October 12 investor call to reveal Phase 3 EXPAND topline results for LIVMARLI in ultra-rare cholestatic liver diseases

Market Chameleon (Mon, 12-Oct 11:45 AM)

Mirum Pharmaceuticals sets October 12 investor call to share Phase 3 EXPAND topline results for LIVMARLI in ultra-rare cholestatic liver diseases

Market Chameleon (Mon, 12-Oct 7:07 AM)

Mirum’s brelovitug clears AZURE-1 Phase 3 primary endpoint, with 0% response in delayed-treatment arm

Market Chameleon (Mon, 28-Sep 8:17 AM)